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Objective: Describe the presence of CTX-M-1 phylogenetic subgroup extended-spectrum
-lactamases (ESBL), associated with TEM and SHV genes, and the gene encod-
ing cephalosporinase, CMY-2 in Escherichia coli and Klebsiella pneumoniae isolates from
community-acquired urinary tract infections.
Methods: 102 E. coli and 21K. pneumoniae were collected from patients with culture-proven
urinary tract infection (UTI), during February and March, 2011. Antimicrobial susceptibility
test was performed by disk diffusion according to the standards of the Clinical Laboratory
Standard Institute. Screening for cephalosporins-resistant E. coli and K. pneumoniae was per-
formed by PCR assay for blaTEM, blaSHV, blaCTX-M-1,-2,-8,-9, blaPER-2 and blaCMY-2 genes. Statistical
analysis was performed by chi-squared test and multivariate logistic regression analysis.
Results: ESBL production was detected in 12 (11.7%) E. coli and four (19%) K. pneumoniae iso-
lates. TEM ESBLs were detected in seven E. coli and three K. pneumoniae isolates. SHV ESBLs
were found in four K. pneumoniae isolates. CTX-M-1 phylogenetic subgroup was positive
in seven E. coli and three K. pneumoniae isolates. CMY-2 -lactamase gene was detected in
nine E. coli and one K. pneumoniae isolates. A signiﬁcant association of ESBL expression in
E. coli was observed with resistance to tobramycin (p≤ 0.001), tetracycline (p=0.043), and
ciproﬂoxacin (p≤ 0.001). In K. pneumoniae isolates, signiﬁcant association was found with
resistance to tobramycin and ciproﬂoxacin (p=0.006), and trimethoprim-sulfamethoxazole
(p= 0.043). Multivariate analyses did not show association between ESBL production in E. coli
and K. pneumoniae, and resistance to non--lactams drugs.
Conclusions: CTX-M ESBL in uropathogens isolated from the community is cause for concerndue to the enormous potential for multidrug resistance from strains that produce these
enzymes, which could lead to failure of empirically-administered therapies and develop-
ment of complicated UTIs.
© 2012 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND∗ Corresponding author at: Universidad de Córdoba, Institute for Tropi
230002, Colombia.
E-mail address: pjmartinezr@hotmail.com (P. Martinez).
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ntroduction
nfections caused by extended-spectrum -lactamases
ESBLs)-producing E. coli and K. pneumoniae have been
escribed in the hospital setting,1 although during the last
ecade these organisms have begun to disseminate into the
ommunity, becoming an emerging public health problem.2
SBLs are enzymes commonly associated with TEM and
HV. However, many E. coli and K. pneumoniae isolates pos-
ess the gene encoding ampC cephalosporinase.3 Moreover,
TX-M-type ESBLs have emerged within the community,
articularly among E. coli and K. pneumoniae isolated from
rinary tract infections (UTIs), with a widespread prevalence
nd multidrug resistance in many countries worldwide.2,4
ultidrug resistance expressed by CTX-M producing isolates
rom the community is often associated with the presence
f multiple ESBLs genes, as well as aminoglycoside and
uinolone resistance genes,5,6 thereby limiting the choice of
ffective antimicrobial drugs.7
The aim of this study was to describe the presence of the
TX-M-1 phylogenetic subgroup ESBL associated with TEM
nd SHV genes and the gene encoding cephalosporinase,
MY-2, in E. coli and K. pneumoniae isolates from community-
cquired UTIs.
aterials and methods
acterial isolates
uring a period of two months (February and March) in
011, 123 isolates of enterobacteria (102 Escherichia coli and
1 Klebsiella pneumoniae), were collected from patients with
ulture-proven UTI evaluated in four clinical microbiology
aboratories in Valledupar, Colombia. Cultures were obtained
rom midstream-collected urine. A uroculture was considered
ositive when it presented a bacterial count of more than
00,000 colony-forming units (CFU)/mL in a urine specimen
ollected midstream.8 E. coli and K. pneumoniae identiﬁcation
as performed according to conventionalmethod.9 This study
as based on laboratory records and not on medicals records.
rganisms were isolated from non-hospitalized patients dur-
ng an outpatient visit to any of the four clinical microbiology
aboratories.
This study did not require an approval from the Ethics
ommittee of Institute for Tropical Biological Research from
niversidad de Córdoba, Colombia.
usceptibility testing and ESBL detection
ntimicrobial susceptibility and interpretation were per-
ormed by disk diffusion according to Clinical Laboratory
tandard Institute (CLSI).10 The antimicrobials used were:
iperacillin-tazobactam (100g/10g), ceftazidime (30g),
eftriaxone (30g), cefepime (30g), aztreonam (30g),
efoxitin (30g), ertapenem (10g), imipenem (10g),
obramycin (10g), ciproﬂoxacin (5g), trimethoprim-
ulfamethoxazole (25g), and tetracycline (30g) from Oxoid,
asingstoke, United Kingdom. ESBL phenotype was detected2;16(5):420–425 421
by interpretation of the CLSI criteria and disk combination
method.11 E. coli ATCC® 25922 and K. pneumoniae ATCC®
700603 were used as control strains.
PCR ampliﬁcation
Screening of cephalosporins-resistant E. coli and K. pneu-
moniae isolates was performed by PCR assay for blaTEM,
blaSHV, blaCTX-M-1, blaCTX-M-2, blaCTX-M-8, blaCTX-M-9, blaPER-2 and
blaCMY-2 genes using the primers described elsewhere.12–16
Statistical analysis
Astatistical comparison of the frequencies of ESBL presence in
E. coli andK. pneumoniae isolateswas conducted by chi-squared
test and multivariate logistic regression analysis. A value of
p<0.05 was considered signiﬁcant. All statistical calculations
were performed by using the Statistical Analysis System ver-
sion 9.1.3 (SAS, Cary, North Carolina, USA).
Results
Antibiotic susceptibility
Susceptibility proﬁle expressed by 123 enterobacteria isolates
(102 E. coli and 21K. pneumoniae) is shown in Table 1. E. coli
isolates included in this study presented resistance to broad-
spectrum cephalosporins in 23.8% of cases. In K. pneumoniae
the resistance rate to broad-spectrum cephalosporins was
12.7%. Resistance expressed by E. coli and K. pneumoniae iso-
lates was of substantial level to non--lactam agents (Table 1).
None of the strains were resistant to carbapenems.
Characteristics of cephalosporins-resistant enterobacteria
Eighteen broad-spectrum cephalosporins-resistant isolates
were tested by disk combination method, and ESBL produc-
tion was found in 11 E. coli (10.7%) and four K. pneumoniae (19%)
isolates by phenotypic conﬁrmation test, as the zone of inhi-
bition increased in presence of clavulanic acid. Three isolates
showed full resistance to third-generation cephalosporins
and to a combination of both cefotaxime and ceftazidime
with clavulanic acid, a phenotype consistent with AmpC -
lactamase production (Table 2).
Molecular analysis by ampliﬁcation of puriﬁed DNA in 18
cephalosporins-resistant isolates yielded a PCR product with
speciﬁc primers for blaTEM, blaSHV and blaCTX-M-1 genes in 16
isolates. The molecular method found one additional ESBL-
positive E. coli isolate that the phenotypic method had not
detected (Table 2). Therefore, ESBL production was detected
in 12 (11.7%) E. coli isolates; blaCTX-M-2, blaCTX-M-8, blaCTX-M-9,
and blaPER-2 were not detected by PCR screening. TEM ESBLs
were detected in ten ESBL producers (seven E. coli and three
K. pneumoniae). SHV ESBLs were found in four K. pneumoniae
isolates. PCR ampliﬁcation by CTX-M type ESBL was posi-
tive for CTX-M-1 phylogenetic subgroup in seven E. coli and
three K. pneumoniae. CMY-2 -lactamase gene was detected in
nine E. coli and one K. pneumoniae isolates. A combination of
422 braz j infect d i s . 2012;16(5):420–425
Table 1 – Percentage of antibiotic susceptibility expressed by E. coli and K. pneumoniae isolates.
Antimicrobial drug Breakpoint (mm) E. coli K. pneumoniae
%R %I %S %R 95% CI %R %I %S %R 95% CI
Ceftazidime 18-20 12.7 0 87.3 7.2-21.1 23.8 0 76.2 9.1-47.5
Ceftriaxone 20-22 12.7 0 87.3 7.2-21.1 23.8 0 76.2 9.1-47.5
Cefepime 15-17 12.7 0 87.3 7.2-21.1 23.8 0 23.8 9.1-47.5
Aztreonam 18-20 12.7 0 87.3 7.2-21.1 23.8 0 23.8 9.1-47.5
Ertapenem 20-22 0 0 100 0.0-4.5 0 0 100 0.3-25.9
Imipenem 20-22 0 0 100 0.0-4.5 0 0 100 0.0-19.2
Tobramycin 13-14 21.6 0 78.4 14.3-31.1 28.6 0 71.4 12.2-52.3
Amikacin 15-16 11.8 0 88.20% 6.5-20.1 14.3 0 85.7 3.8-37.4
Ciproﬂoxacin 16-20 38.2 0 61.8 28.9-48.4 33.3 0 66.7 15.5-56.9
SXT 11-15 50 0 50 40.0-60.0 23.8 0 76.2 9.1-47.5
Tetracycline 12-14 60.8 0 39.2 50.6-70.2 19 0 81 6.3-42.5
R, resistance; I, intermediate resistance; S, susceptible; SXT, trimethoprim-sulfamethoxazole; CI, conﬁdence interval.
Table 2 – Molecular and phenotypic characteristics of third-generation cephalosporins-resistant E. coli and K. pneumoniae
isolates.
Pathogen No. isolates Disk combination
method
ESBL genes Susceptibility by disk diffusion CLSI
blaTEM blaSHV blaCTX-M-1 blaCMY-2 AK FOX CIP ETP IPM TZP TCY TOB SXT
E. coli
35 + + - + + S S R S S S R R S
40 + - - + + S S R S S R R R R
102 + + - - + S R R S S S S S S
108 + - - - - S S R S S R R S R
525 - - - - + R R R S S R R R R
527 + + - + + S S R S S S R S R
551 + + - + + S S R S S S R R R
576 + - - - - S S R S S S R S S
580 - - - + + S R R S S R R R R
612 + - - + + S S R S S S R R R
673 + + - - - S S R S S R R R R
678 + + - + + R R R S S R R R R
698 + + - - + S S R S S S R R R
K. pneumoniae
111 + - + + - S S R S S R S R R
587 + + + + - S S R S S S R R R
672 - - - - + R R S S S R S S S
710 + + + + - R S R S S R S R R
5125 + + + - + R R R S S R S R S
IPM,
uscepAK, amikacin; FOX, cefoxitin; CIP, ciproﬂoxacin; ETP, ertapenem;
tobramycin; SXT, trimethoprim-sulfamethoxazole; R, resistance; S, s
ESBLs and AmpC -lactamase genes was found in ten isolates
(Table 2).
Four E. coli isolates were carrying both blaTEM and blaCTX-M-1
ESBLs genes, and all were positive for blaCMY-2. Two of four
ESBL producing K. pneumoniae was carrying blaTEM, blaSHV and
blaCTX-M-1 genes, another isolate was a producer of ESBL types
SHV andCTX-M-1 subgroup, and one of the four isolates (5125)
carrying blaTEM also contained the blaSHV gene, this being a
single K. pneumoniae isolate positive for blaCMY-2 (Table 2).
A signiﬁcant association of ESBL expression in E. coli
was observed with resistance to tobramycin (p≤ 0.001), tetra-
cycline (p=0.043), and ciproﬂoxacin (p≤ 0.001) (Table 3).
A positive test result in K. pneumoniae isolates was sig-
niﬁcantly associated with resistance to tobramycin and
ciproﬂoxacin (p=0.006), and trimethoprim-sulfamethoxazoleimipenem; TZP, piperacillin/ tazobactam; TCY, tetracycline; TOB,
tible; +, positive; -, negative.
(p = 0.043) (Table 3). Multivariate analyses did not show any
association between ESBL production in E. coli and K. pneumo-
niae, and resistance to non--lactams drugs (Table 4).
Discussion
Community-acquired UTIs caused by ESBL-producing orga-
nisms are a cause of concern due to the clinical failure of
empirical treatment protocols. This study shows two main
pathogens causing UTIs in the community (E. coli and K.
pneumoniae). The results show that expressed resistance to
quinolones (ciproﬂoxacin) is similar among community iso-
lates of E. coli and K. pneumoniae, 33% and 38%, respectively
(Table 1). However, signiﬁcant resistance was presented to
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Table 3 – Crude association between antimicrobial drug resistance and positive test result for ESBL in E. coli and K.
pneumoniae.
Antimicrobial agent E. coli (n = 102), OR (95% CI) p K. pneumoniae (n = 21), OR (95% CI) p
Amikacin 0.65 (0.07-5.56) 0.932 16 (0.95-267) 0.140
Tobramycin 10.85 (2.87-40.99) < 0.001 55.8 (2.24-1,386.31) 0.006
Tetracycline 8.41(1.04-67.94) 0.043 1.55 (0.11-20.61) 0.710
Ciproﬂoxacin 57.7 (3.29-1,009.91) < 0.001 55.8 (2.24-1,386.31) 0.006
SXT 3.42 (0.87-13.50) 0.124 22.5 (1.50-335.33) 0.043
OR, odds ratio; CI, conﬁdence interval; SXT, trimethoprim-sulfamethoxazole.
Variables with p<0.05 were considered signiﬁcant.
Table 4 – Association of antimicrobial drug resistance and presence of ESBL in E. coli and K. pneumoniae.
Antimicrobial drug Estimate OR (95% CI) p*
E. coli
Tetracycline -0.23 0.0002 (0.0000-1.2730) 0.812
Ciproﬂoxacin -0.30 0.0001 (0.0000-5.3914) 0.762
Tobramycin -1.55 0.283 (0.058-1.383) 0.119
SXT 0.19 1.230 (0.159-9.509) 0.842
K. pneumoniae
Tetracycline 0.54 7.877 (0.004-12678.32) 0.583
Ciproﬂoxacin -1.64 0.009 (0.00004-2.4168) 0.100
Tobramycin -1.24 0.021 (0.00005-0.0407) 0.212
SXT -0.54 0.119 (0.00005-253.05) 0.586
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∗ by 2 approximation.
rimethoprim-sulfamethoxazole (50%) and tetracycline (60%)
n E. coli isolates, characterizing an alarming resistance to
hese two families of antibiotics.
ESBL production found among community isolates of
. coli was 11.7% and 19% for K. pneumoniae, rates similar
o that found in hospital isolates;1,17 K. pneumoniae is the
ain ESBL-producing organism worldwide.18 In Latin Amer-
can countries, community-acquired ESBLs are starting to
ppear with rates up to 28.7% among E. coli and K. pneu-
oniae isolates,19 while in Europe reported rates are of only
.5% to 5.6%, respectively.20 The presence of ESBL-producing
rinary isolates in the community is a signiﬁcant public
ealth problem that unavoidably increases health care costs
or patients and health care providers due to the use of
arbapenems, since the oral agents (nitrofurantoin and fos-
omycin), used for treatment of UTIs, are unsuitable due to
he enormous resistance-development ability demonstrated
y uropathogens, which has led to a loss of interest in these
rugs. Therefore, carbapenems appear to be the drugs of
hoice for the treatment of UTIs caused by ESBL-producing
. coli and K. pneumoniae, considering their rational use.21,22
In Colombia, the prevalence of community-acquired ESBL-
roducing E. coli and K. pneumoniae is not well known;
he ﬁndings of TEM and SHV enzymes in this study show
he spread of these enzymes in hospital and community
solates in Colombia.23 However, the presence of community-
cquired CTX-M-producing Enterobacteriaceae (seven E. coli
nd three K. pneumoniae), is of concern especially in E. coli,
ecause these enzymes are commonly encoded by plas-
ids. Besides, there is the possibility that isolates found in
his study are associated with well-characterized ST131 andal.
ST405, which are multidrug-resistant intercontinental clones
responsible for the dissemination of blaCTX-M-15, as previously
reported in Colombia.24 Multidrug-resistance expressed by
ESBL-producing Enterobacteriaceae in this study was presented
to aminoglycosides, trimethoprim-sulfamethoxazole, tetracy-
cline, and quinolones (Table 2).
ESBL-producing K. pneumoniae strains are more related
to hospital outbreaks. However, the current distribution of
ESBL carrying microorganisms in patients with community-
acquired UTIs is a generalized problem, thus producing
a ﬂow of isolates from the community to the hospital
setting.25 Likewise, the strains of E. coli and K. pneumoniae
that harbored multiple ESBL genes are important, because
it has been reported that isolates carrying multiple ESBL
genes had a greater resistance to various classes of antibi-
otic mediated through acquisition of genes located on
mobile genetic elements such as plasmids, transposons, or
integrons.5,26 Furthermore, the fact that they harbor mul-
tiple ESBL genes in combination with the gene encoding
cephalosporinase CMY-2 could explain the cefoxitin resis-
tance (four E. coli and two K. pneumoniae), as reported in
previous studies that have shown the blaCMY-2 gene linked
downstream with the promoter sequence ISECP1,27 increas-
ing the likelihood of therapeutic failures and difﬁculty for
laboratory phenotypic detection of ESBL.28,29Finally, resis-
tance expressed by E. coli and K. pneumoniae isolates, and
molecular conﬁrmation of ESBL genes were analyzed using
statistical models to measure the crude association between a
positive result for ESBL in isolates of E. coli and resis-
tance to tobramycin (p≤ 0.001), tetracycline (p=0.025) and
ciproﬂoxacin (p=0.01) (Table 3). In K. pneumoniae isolates, an
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association was found between a positive result for ESBL and
resistance to tobramycin (p=0.002), ciproﬂoxacin (p=0.002),
and trimethoprim-sulfamethoxazole (p=0.027) (Table 3). How-
ever, in multivariate analysis did not show non--lactam
drugs as an independent variable. This ﬁnding suggests that
non--lactams resistance remained independently associated
with ESBL, but for reasons unrelated to ESBL genes. Studies
have shown that non--lactam and -lactam (ESBL) resistance
encoding genes are located in plasmids.13,30 This common
location may explain the resistance to previously mentioned
antibiotics. Nevertheless, it is interesting that resistance to
ciproﬂoxacin was associated with presence of ESBL and resis-
tance to other antibiotic classes (Table 2). To some extent, this
could be explained by its extensive use as an empirical drug
for treatment of UTIs, resulting in strong selective antimicro-
bial pressure in the community. Similar data were found in
previous studies.31–33
Conclusion
Detection of CTX-M ESBL in uropathogens isolated from the
community is of concern because of the enormous poten-
tial for multidrug resistance of strains that produce these
enzymes, especially if E. coli isolates from this study could
be related to the intercontinental clones ST131 and ST405,
because empirically administered therapies will fail, which
could lead to complicated UTIs.
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